PEOPLE - SpectraScience (US) makes appointment:
This article was originally published in Clinica
Executive Summary
SpectraScience (San Diego, California), developer of a biopsy system (WavSTAT Optical Biopsy System) to diagnose tissue for cancer, has appointed John Pappajohn to its board of directors. Mr Pappajohn, owner of Pappajohn Capital Resources (venture capital), is president and principal stockholder of Equity Dynamics (financial consulting). He currently serves as a director for more than 40 public healthcare companies.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.